Ziprasidone drug data and news

---

Recent Developments in Antipsychotic Use in Adults  Apr 20, 2006
The most recent additions to the antipsychotic armamentarium, ziprasidone (Geodon) and aripiprazole (Abilify), differ from the previously available products in ... - Psychiatric Times,

Understanding and Managing Psychosis in Late Life  May 15, 2006
...prescribed antipsychotics. Studies of ziprasidone (Geodon) in this population have not yet been published. Aripiprazole (Abilify ... - Psychiatric Times,

Aripiprazole in the Treatment of Patients With Borderline ...  May 10, 2006
Text]. Anghelescu I, Wolf J: Successful switch to aripiprazole after induction of hyperprolactinemia by ziprasidone: a case report. ... - Am J Psychiatry (subscription)

Behavioral and Pharmacologic Treatment of Aggression in Children ...  May 10, 2006
Clozapine (Clozaril), quetiapine (Seroquel), olanzapine (Zyprexa) and ziprasidone (Geodon) have been evaluated in small or uncontrolled studies and case ... - Psychiatric Times,

Innovations: Geriatric Psychiatry: Diagnosis and Treatment of ...  May 10, 2006
Olanzapine has also been shown to effective and well tolerated at dosages of 5 to 10 mg per day (8). Data for quetiapine, ziprasidone, and aripiprazole are ... - Psychiatric Services (subscription)

Self-Mutilation of Fingers After Cervical Spinal Cord Injury  May 9, 2006
We recommended a trial of ziprasidone and individual psychotherapy. ... Ziprasidone was recommended in this case to make use of its dopamine-antagonism properties. ... - Psychosomatics (subscription)

Antipsychotic Drug Use Growing Fastest Among Children  May 2, 2006
...receiving the latest generation of antipsychotics - known as atypical antipsychotics, including risperidone, olanzapine, clozapine, ziprasidone and quetiapine ... - YubaNet,

Management of Acute Undifferentiated Agitation in the Emergency ...  Apr 26, 2006
We have read with interest the recent article 1 that compared the efficacy of droperidol, ziprasidone, and midazolam for sedation in the emergency department ... - AEM (subscription)

Schizophrenia gene function offers hope for drug R&D  Apr 23, 2006
The newer atypical antipsychotic medications (such as clozapine, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazole) are usually preferred over ... - DrugResearcher.com,

Droperidol Use in the Emergency Department Is Not Safe  Apr 26, 2006
Biros M. Management of acute undifferentiated agitation in the emergency department: A randomized double-blind trial of droperidol, ziprasidone, and midazolam. ... - AEM (subscription)

Pfizer profits soar despite slipping revenues  Apr 20, 2006
But strong growth from newer products such as schizophrenia drug Geodon (ziprasidone), up 32% to $182 million, and Lyrica (pregabalin) for epilepsy and pain ... - Pharma Times (subscription),

Drug-drug interactions can be pharmacodynamic (combined pharmacologic effects) or pharmacokinetic (alteration of plasma levels). The risks of using ziprasidone in combination with other drugs have been evaluated as described below. Based upon the pharmacodynamic and pharmacokinetic profile of ziprasidone, possible interactions could be anticipated:

Pharmacodynamic Interactions

1. Ziprasidone should not be used with any drug that prolongs the QT interval .
2. Given the primary CNS effects of ziprasidone, caution should be used when it is taken in combination with other centrally acting drugs.
3. Because of its potential for inducing hypotension, ziprasidone may enhance the effects of certain antihypertensive agents.
4. Ziprasidone may antagonize the effects of levodopa and dopamine agonists.

Pharmacokinetic Interactions

The Effect of Other Drugs on Ziprasidone

Carbamazepine Carbamazepine is an inducer of CYP3A4; administration of 200 mg BID for 21 days resulted in a decrease of approximately 35% in the AUC of ziprasidone. This effect may be greater when higher doses of carbamazepine are administered.

Ketoconazole Ketoconazole, a potent inhibitor of CYP3A4, at a dose of 400 mg QD for 5 days, increased the AUC and C _max of ziprasidone by about 35-40%. Other inhibitors of CYP3A4 would be expected to have similar effects.

Cimetidine Cimetidine at a dose of 800 mg QD for 2 days did not affect ziprasidone pharmacokinetics.

Antacid The coadministration of 30 mL of MAALOX with ziprasidone did not affect the pharmacokinetics of ziprasidone.

In addition, population pharmacokinetic analysis of schizophrenic patients enrolled in controlled clinical trials has not revealed evidence of any clinically significant pharmacokinetic interactions with benztropine, propranolol, or lorazepam.

Effect of Ziprasidone on Other Drugs

In vitro studies revealed little potential for ziprasidone to interfere with the metabolism of drugs cleared primarily by CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, and little potential for drug interactions with ziprasidone due to displacement.

Lithium Ziprasidone at a dose of 40 mg BID administered concomitantly with lithium at a dose of 450 mg BID for 7 days did not affect the steady-state level or renal clearance of lithium.

Oral Contraceptives Ziprasidone at a dose of 20 mg BID did not affect the pharmacokinetics of concomitantly administered oral contraceptives, ethinylestradiol (0.03 mg) and levonorgestrel (0.15 mg).

Dextromethorphan Consistent with in vitro results, a study in normal healthy volunteers showed that ziprasidone did not alter the metabolism of dextromethorphan, a CYP2D6 model substrate, to its major metabolite, dextrorphan. There was no statistically significant change in the urinary dextromethorphan/dextrorphan ratio.